Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN)
← catalyst calendarNCT06809764 · readout in 176 d
Sponsored by Daiichi Sankyo (industry) · 4568.T — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
150estimated
Sites
36
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-02-21 | actual | When the study began enrolling |
| Primary completion | 2027-02-12 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-02-12 | estimated | The whole study's end, after follow-up |
| First posted | 2025-02-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Non-small Cell Lung Cancer
Intervention
- Other: No drug
Primary outcome
what the primary-completion date above is the date OFProgression-free survival (PFS) by Investigator Assessment in Real-world Setting (rwPFS)
measured Baseline up to approximatley 2 years
Permalink · 4568.T's whole pipeline · Catalyst calendar · Every registered study · What changed